期刊文献+

比较环孢菌素与英夫利息单抗治疗重症难治性溃疡性结肠炎疗效的荟萃分析 被引量:5

Meta-analysis of efficacy of ciclosporin and infliximab in treatment of severe refractory ulcerative colitis
暂未订购
导出
摘要 目的比较环孢菌素与英夫利息单抗治疗重症难治性溃疡性结肠炎后结肠切除率及并发症发生率。方法检索PubMed、EMBASE、Cochrane Library数据库中所有关于比较环孢菌素与英夫利息单抗治疗重症难治性溃疡性结肠炎的研究。应用比值比(0R)及其95%CI为疗效分析统计量。用Review Manager5.1软件对符合纳入标准的研究通过固定效应模式或随机效应模式进行荟萃分析,比较使用环孢菌素和英夫利息单抗后的3个月、12个月的结肠切除率及并发症的发生率。结果共9篇文献纳入荟萃分析。其中,6篇为回顾性研究,2篇为前瞻性研究,1篇为多中心随机对照研究。对于3个月的结肠切除率,0R值为1.48(95%CI:0.61~3.62,P=0.39);对于12个月的结肠切除率,OR值为1.36(95%CI:0.59~3.12,P=0.47);对于并发症的发生率,0R值为0.88(95%CI:O.54~1.41,P=0.59)。结论英夫利息单抗和环孢菌素在治疗重症难治性溃疡性结肠炎后的结肠切除率和并发症的发生率差异均无统计学意义。 Objective To compare the rate of colectomy and complication between patients treated with ciclosporin and infliximab for severe refractory ulcerative colitis. Methods All relevant studies were searched by PubMed, EMBASE, and Coehrane Library databases. Odds ratio with 95% CI were calculated using fixed or random effect model in Review Manager version 5.1. Primary items were 3- and 12-month colectomy and complication. Results Overall, 9 papers were included in the Meta-analysis. Among them, 6 were retrospective studies, 2 were prospective studies, and 1 was multi-center randomized controlled trial. For the 3-month coleetomy rate, OR was 1.48 (95% CI: O. 61 -3.62, P =0.39) ; for the 12-month colectomy rate, OR was 1.36 (95% CI: O. 59 - 3.12, P =0.47) ; for the complication, OR was 0.88 (95% CI: O. 54 - 1.41, P = 0.59). Conclusion Colectomy and complication rates are similar between patients treated with ciclosporin and infliximab.
出处 《胃肠病学和肝病学杂志》 CAS 2014年第2期153-157,共5页 Chinese Journal of Gastroenterology and Hepatology
基金 幽门螺旋杆菌通过胃间质转分化参与Treg诱导免疫逃逸机制的研究(81100267)
关键词 溃疡性结肠炎 英夫利息单抗 环孢菌素 治疗 Meta分析 Ulcerative colitis Infliximab Ciclosporin Treatment Meta-analysis
  • 相关文献

参考文献23

  • 1Dinesen LC, Walsh AJ, Protic MN, et al. The pattern and outcome of acute severe colitis [J]. J Crohns Colitis, 2010, 4(4) : 431-437.
  • 2Turner D, Walsh CM, Steinhart AH, et al. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression [ J ]. Clin Gastroenterol Hepatol, 2007, 5 (1): 103-110.
  • 3Ptaehcinski R J, Burckart GJ, Venkataramanan R. Cyclosporine [J].Drug Intell Clin Pharm, 1985, 19(2) : 90-100.
  • 4Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy [ J]. N Engl J Med, 1994, 330(26) : 1841-1845.
  • 5Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis [ J]. N Engl J Med, 2005, 353 (23) : 2462-2476.
  • 6Maser EA, Deeonda D, Lichtiger S, et al. Cyelosporine and infliximab as rescue therapy for each other in patients with steroid-refractory ulcer- ative colitis [ J ]. Clin Gastroenterol Hepatol, 2008, 6 ( 10 ) : 1112-1116.
  • 7Leblanc S, Allez M, Seksik P, et al. Successive treatment with cyclos- porine and infliximab in steroid-refractory ulcerative colitis [ J]. Am J Gastroenterol, 2011, 106(4): 771-777.
  • 8Schluender SJ, Ippoliti A, Dubinsky M, et al. Does infliximab influ- ence surgical morbidity of ileal pouch-anal anastomosis in patients with ulcerative colitis? [ J ]. Dis Colon Rectum, 2007, 50 (11): 1747-1753.
  • 9Daperno M, Sostegni R, Scaglione N, et al. Outcome of a conservative approach in severe ulcerative colitis [ J]. Dig Liver Dis, 2004, 36 (1): 21-28.
  • 10Radford-Smith G, Croft A, Doecke J, et al. Outcomes of salvage therapy for acute severe ulcerative colitis: Cyclosporin versus inflix- imab [ J]. Inflammatory Bowel Diseases, 2009, 15: S43-S44.

二级参考文献3

共引文献9

同被引文献53

引证文献5

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部